A Phase III Randomized, Double-Blind, Placebo-Controlled Study of Sorafenib as Adjuvant Treatment for Hepatocellular Carcinoma After Surgical Resection or Local Ablation

Trial Profile

A Phase III Randomized, Double-Blind, Placebo-Controlled Study of Sorafenib as Adjuvant Treatment for Hepatocellular Carcinoma After Surgical Resection or Local Ablation

Completed
Phase of Trial: Phase III

Latest Information Update: 23 Apr 2017

At a glance

  • Drugs Sorafenib (Primary)
  • Indications Liver cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms STORM
  • Sponsors Bayer; Bayer HealthCare
  • Most Recent Events

    • 05 Jan 2015 Status changed from active, no longer recruiting to completed according to ClinicalTrials.gov record.
    • 14 Sep 2014 Planned End Date changed from 1 Mar 2020 to 1 Dec 2014, according to ClinicalTrials.gov record.
    • 11 Mar 2014 Primary endpoint 'Disease-free-survival' (recurrence-free survival) has not been met according to a Bayer HealthCare and Onyx Pharmaceuticals media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top